BioStock: Spago's phase I/IIa cancer trial progressing steadily
The positive momentum for Spago Nanomedical carries over into 2024 as the company announces continued progress with its Tumorad phase I/IIa trial. The independent data monitoring committee has recommended a dose escalation with the company's radiopharmaceutical drug candidate 177Lu-SN201 for the treatment of advanced cancer.
Read the article at biostock.se:
Spago's phase I/IIa cancer trial progressing steadily - BioStock (https://www.biostock.se/2024/01/spagos-phase-i-iia-cancer-trial-progressing-steadily/)
This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se/en/